

## HLTH – 805

### Big Data and Analytics for Health and Healthcare

#### Assignment 6.2: Use Case Template

- Sowmiya Kanagaraj

Analytic Use Case Template	
<b>Use Case Title:</b>	Device and Drug Comparative Effectiveness
<b>Description:</b>	In this scenario, the primary objective is to tackle the imperative task of assessing and contrasting the efficacy of medical apparatus and pharmaceutical compounds within the realm of clinical application.
<b>Type (Clinical, Administrative, Both)</b>	Clinical
<b>Current State vs Ideal State: Describe, compare/contrast</b>	<p><b>Current State:</b> In the contemporary healthcare landscape, clinical determinations pertaining to the choice of medical apparatus and pharmaceutical remedies are primarily forged upon inconclusive anecdotal substantiation, data, or information disseminated by manufacturers. This sector frequently lacks the precision and thoroughness inherent in a methodical assessment and juxtaposition of the efficacy of these therapeutic interventions (Martínez-García &amp; Hernández-Lemus, 2022). The paucity of a standardized comparative efficacy analysis contributes to the persistence of suboptimal protocols and potentially undermines the caliber of patient care.</p> <p><b>Ideal State:</b> In this envisaged forthcoming state, healthcare practitioners possess access to a well-entrenched and all-encompassing framework for comparative efficacy analysis. Guided by robust data-driven discernments, healthcare professionals can formulate decisions that assimilate both clinical effectiveness and cost-efficiency, ultimately culminating in the enhancement of patient care and the optimization of resource allocation (Elodie Baumfeld-André et al., 2022). This aspirational state envisions a healthcare milieu wherein determinations are founded upon meticulous scrutiny, thereby curtailing disparities in practice and ensuring that patients are administered the most efficacious and resource-sparing interventions.</p> <p><b>Compare / Contrast:</b> The comparative analysis of the current state and the aspirational state accentuates the profound influence that the implementation of a comprehensive framework for comparative efficacy analysis can wield over the realm of healthcare. In the prevailing status quo, determinations are frequently formulated with meager information, leading to variances in clinical practices and prospective</p>

	<p>ineffectiveness. Conversely, the aspirational state signifies a paradigmatic shift toward data-driven decision-making. It guarantees that healthcare providers have access to evidence-based discernments, fostering judicious choices. This transition not only augments patient care but also harbors the potential to diminish healthcare expenditures through the judicious allocation of resources.</p>
<b>Stakeholders</b>	<p><b>Healthcare Providers (Physicians, Nurses, Pharmacists) and Hospital Administrators:</b> Their stake lies in accessing dependable comparative effectiveness data to make judicious treatment decisions, thereby ensuring the delivery of optimal care to their patients (Sarsen et al., 2020).</p> <p><b>Patients:</b> For patients, the primary concern revolves around receiving the most efficacious and cost-efficient medical interventions.</p> <p><b>Medical Device Manufacturers:</b> The interests of medical device manufacturers are closely tied to demonstrating the effectiveness and value of their products in clinical practice (Saesen et al., 2020). This, in turn, can exert considerable influence on product adoption and market demand.</p> <p><b>Regulatory Agencies (FDA, etc.):</b> Regulatory bodies, such as the FDA, are steadfastly committed to ensuring the safety and efficacy of medical devices and drugs.</p>
<b>Strategy Alignment</b>	<p><b>Advancing Evidence-Based Medicine:</b> This utilization scenario buttresses the strategic drive towards advancing evidence-based medicine. By furnishing healthcare practitioners with meticulously researched insights and counsel in the realm of medical apparatuses and pharmaceuticals, it empowers clinicians to engage in judicious decision-making steeped in empirical findings and real-world outcomes (Dhruva et al., 2018).</p> <p><b>Streamlining Resource Allocation:</b> This utilization case makes a substantial contribution to the optimization of resource allocation strategies. Through the discernment of the most efficacious medical interventions, it facilitates the precision-targeting of resources, consequently mitigating wastage and curtailing superfluous expenditures on less efficacious treatment modalities (Dhruva et al., 2018).</p> <p><b>Elevating the Patient Experience:</b> The enhancement of clinical decision-making processes arising from the application of this use case translates directly into superior clinical outcomes, a diminution in adverse events, and a heightened degree of satisfaction with their healthcare journey (Young &amp; Smith, 2022).</p>
<b>Barriers/Obstacles</b>	<p><b>Privacy and Security Apprehensions:</b> These concerns may impose restrictions on accessing the vital healthcare information indispensable for comprehensive analysis (Fogel, 2018). The prudent course of action involves the implementation of robust data anonymization and encryption techniques and adhering meticulously to pertinent data protection regulations.</p>

	<p><b>Resource Limitations:</b> These limitations may encumber the processes of data collection, analysis, and dissemination (Fogel, 2018). To surmount this obstacle, a judicious approach entails the formulation of a cogent cost-benefit analysis.</p>
<p><b>Importance of Use Case: Describe</b></p>	<p><b>Ranking:</b> Extremely High</p> <p>The efficacious realization of this utilization scenario holds paramount importance as it possesses the capacity to substantially ameliorate the process of clinical decision-making, elevate patient outcomes, and optimize the allocation of resources, thus constituting an indispensable catalyst for the comprehensive quality and durability of healthcare services.</p>
<p><b>Clinical and/or Business Problem / Decision involved and/or impacted</b></p>	<p><b>Decision:</b> Opting for the most efficacious and cost-effective medical interventions for patients.</p> <p><b>Impact:</b> This transformation is projected to yield a more methodical and evidence-driven approach to healthcare interventions, culminating in enhanced patient outcomes and fiscal efficiencies within the healthcare ecosystem.</p>
<p><b>Clinical and/or Business Process(es) involved and/or impacted:</b></p>	<p><b>Medicinal Prescription Procedure:</b> The analytical solution is poised to ameliorate the medicinal prescription process through the provision of data-driven counsel to healthcare practitioners regarding the most efficacious and economically prudent pharmaceuticals. This shall culminate in an enhanced selection of medications and the potential attenuation of pharmaceutical errors.</p> <p><b>Patient Egress Procedure:</b> The recommendations emanating from the use case, pertaining to efficacious medical instruments and pharmaceuticals, can expedite the seamless orchestration of patient egress. This shall guarantee that patients are discharged with the most judicious interventions tailored to their post-hospitalization convalescence, thus conceivably curtailing readmission rates.</p> <p><b>Enrollment Process for Clinical Trials:</b> The deployment of the use case can potentially perturb the process of enrolling patients in clinical trials by discerning patients who may reap benefits from participation predicated upon their medical antecedents and therapeutic alternatives. This may result in an augmentation of patient participation rates in clinical trials.</p>
<p><b>Clinical and/or Business Rule(s):</b></p>	<p><b>Clinical guidelines and protocols:</b></p> <p>Data Inclusion: Pertinent patient data points harmonious with specific clinical directives and procedural mandates necessitate incorporation into the analytical framework.</p> <p>Data Exclusion: Information unrelated to the precise clinical protocols under scrutiny warrants exclusion from consideration.</p> <p>Summarization: The synthesis of data must be executed in alignment with the fidelity to clinical directives, quantified through metrics such as the proportion of patients who have received recommended therapeutic regimens.</p> <p>Visualization: The explication of adherence to clinical directives</p>

across diverse patient cohorts can be artfully manifested through the employment of visual aids, encompassing bar graphs and heatmaps.  
 Derived Information: The computation of adherence scores or indices predicated upon the proximity of patients' medical care to established protocols is a requisite endeavor.

If/Then Logic: Patients who satisfy the stipulations delineated within the clinical directive are deemed adherent to the prescribed course of therapeutic intervene.

**Reimbursement policies:**

Data Inclusion: Information germane to procedures, services, or treatments subject to reimbursement policies necessitates inclusion in the analytical purview.

Data Exclusion: Data extraneous to the sphere of reimbursement policies should be judiciously excluded.

Summarization: Data synthesis must transpire with a discerning focus on reimbursement eligibility and payment status, encapsulating the fiscal dimensions of the healthcare landscape.

Visualization: The portrayal of the distribution of reimbursement claims and denials is aptly executed through data visualization.

Derived Information: The computation of the reimbursement rate, signifying the proportion of claims accorded approval for reimbursement, assumes paramount importance.

If/Then Logic: Claims that align with the stipulations enshrined within the reimbursement policy are deemed eligible for monetary compensation; contrariwise, they may encounter denial.

**Regulatory requirements:**

Data Inclusion: Data elements mandated by regulatory authorities for purposes of compliance necessitate inclusion within the ambit of analysis.

Data Exclusion: Data incongruent with the domain of regulatory compliance ought to be scrupulously excluded from consideration.

Summarization: Data synthesis must culminate in an evaluative assessment of compliance rates vis-à-vis specific regulatory prerequisites.

Visualization: The depiction of compliance trends, be it temporally evolving or across diverse facilities, can be artfully conveyed through the medium of visual representation.

Derived Information: The computation of compliance percentages or rates predicated upon the presence or absence of regulatory requisites within the dataset represents a quintessential undertaking.

If/Then Logic: If data portray non-compliance with regulatory mandates, it behooves stakeholders to contemplate remedial actions aimed at aligning with the hallowed standards of regulatory compliance.

<p><b>Action(s) Triggered:</b></p>	<p><b>Data accumulation and consolidation:</b>  Action: Amass and systematize electronic health records (EHR), pharmaceutical consumption patterns, insurance claims information, clinical trial findings, apparatus usage data, and patient-derived outcomes into a unified depository.  Impact: Augmented accessibility to comprehensive healthcare data for comparative efficacy investigations, fostering evidence-based decision-making.</p> <p><b>Comparative efficacy examination:</b>  Action: Assess and juxtapose the therapeutic effectiveness of pharmaceuticals and medical appliances employing advanced machine learning algorithms and intricate statistical evaluations.  Impact: The identification of premier methodologies enables healthcare professionals to make judicious treatment choices.</p> <p><b>Formulation of evidence-backed propositions:</b>  Action: Utilize economic viability modeling and empirical data-driven discernment to proffer suggestions regarding the adoption of evidence-supported medical devices and pharmaceuticals.  Impact: Leverage financial practicality models alongside fact-based insights to generate well-founded recommendations for opting medical contraptions and drugs buttressed by substantial evidence.</p> <p><b>Insights' integration into clinical protocols:</b>  Action: Cultivate avenues for incorporating substantiated suggestions into established clinical workflows and treatment standards.  Impact: The enhancement of consistency and proficiency in healthcare decision-making ultimately betters patient outcomes while potentially reducing overall medical expenses.</p>
<p><b>Data Requirements:  Data, analytics,  analytics plan</b></p>	<p><b>Data:</b>  Drug Utilization Data  Patient-Reported Outcomes  Electronic Health Records (EHR)  Device Utilization Data  Claims Data  Clinical Trial Data</p> <p><b>Analytics:</b>  The utilization scenario employs a multifaceted array of analytical techniques, encompassing:  Statistical Analyses  Machine Learning Algorithms  Cost-Benefit Modeling  Data Visualization Modalities  These analytical methodologies facilitate the harmonization of</p>

	<p>disparate data streams to gauge the relative efficacy of medical devices and pharmaceuticals, assess cost-effectiveness, prognosticate patient responses, and proficiently convey discernments.</p> <p><b>Analytics plan</b> The analytical blueprint delineates the operational blueprint for the utilization scenario:</p> <p>Data Agglomeration and Ingress: Diverse data streams will be amalgamated into a secure data repository. Data Integrity Validation: Rigorous assessments and data rectification protocols will be instated to safeguard precision and uniformity. Risk Mitigation Strategies: Data governance frameworks, cryptographic security, access management protocols, and adherence to privacy edicts will be diligently enforced. Technological Prescriptions: State-of-the-art analytical platforms and cloud-based solutions will be enlisted for data scrutiny. Intervention Imposition: Findings will drive clinical and procurement determinations, with recommendations seamlessly embedded within decision support frameworks. The analytical blueprint orchestrates meticulous data processing, proactive quandary resolution, fidelity to data governance norms, and harmonization with strategic imperatives. This holistic approach is engineered to elevate healthcare decision-making and enhance patient outcomes.</p>
<p><b>Use Case solutions (define, describe)</b></p>	<p><b>Inaugurate a data repository:</b> Forge a centralized depository for healthcare information with the intent of buttressing comparative effectiveness research.</p> <p><b>Formulate analytical models:</b> Employ statistical and machine learning methodologies to scrutinize data, juxtaposing the efficacies of medical contrivances and pharmaceuticals.</p> <p><b>Foster recommendations grounded in empirical evidence:</b> Disseminate actionable insights and counsel to healthcare practitioners, predicated upon the outcomes of the analysis.</p> <p><b>Vigilant surveillance and perpetual refinement:</b> Maintain a continuous vigil over the performance of interventions, adapting recommendations in tandem with the influx of fresh data.</p>
<p><b>Summary findings &amp; recommendations to be presented</b></p>	<p>Comparative effectiveness findings concerning specific medical apparatuses and pharmaceuticals, divulged in a meticulous manner. An analysis of cost-effectiveness, poised to illuminate the decision-making processes entailing procurement.</p> <p>Strategical blueprints for the seamless integration of evidence-based counsel into the arena of clinical practice.</p> <p>A comprehensive blueprint for ongoing scrutiny and assessment, orchestrated to gauge the ramifications of the implemented interventions.</p>

<b>Additional Details:</b>	Further intricacies concerning this employment scenario deserve attention. It signifies a conspicuous opening to enhance the quality of patient care, elevate the acumen that governs healthcare decision-making, and rationalize the allocation of invaluable resources. Its realization hinges upon the collaborative synergy among vested parties, the deployment of robust data analytics, and an unwavering commitment to the ethos of evidence-driven medicine. The execution of this utilization scenario bears the promise of yielding superior patient outcomes and the streamlining of healthcare delivery processes.		
<b>Prepared by:</b>	Sowmiya Kanagaraj	<b>Revised Date:</b>	15 October, 2023

### References

- Dhruva, S. S., Ross, J. S., & Desai, N. R. (2018). Real-World Evidence: Promise and Peril for Medical Product Evaluation. *P & T : A Peer-Reviewed Journal for Formulary Management*, 43(8), 464–472.  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6065494/>
- Elodie Baumfeld-Andre, Carrington, N., Siami, F. S., Jo Carol Hiatt, McWilliams, C., Hiller, C., Surinach, A., Zamorano, A., Pashos, C. L., & Schulz, W. L. (2022). The Current Landscape and Emerging Applications for Real-World Data in Diagnostics and Clinical Decision Support and its Impact on Regulatory Decision Making. 112(6), 1172–1182. <https://doi.org/10.1002/cpt.2565>
- Fogel, D. B. (2018). Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: A review. *Contemporary Clinical Trials Communications*, 11, 156–164. ncbi. <https://doi.org/10.1016/j.conctc.2018.08.001>
- Martínez-García, M., & Hernández-Lemus, E. (2022). Data Integration Challenges for Machine Learning in Precision Medicine. *Frontiers in Medicine*, 8.  
<https://doi.org/10.3389/fmed.2021.784455>
- Saesen, R., Lejeune, S., Quaglio, G., Lacombe, D., & Huys, I. (2020). Views of European Drug Development Stakeholders on Treatment Optimization and Its Potential for Use in Decision-Making. *Frontiers in Pharmacology*, 11.  
<https://doi.org/10.3389/fphar.2020.00043>
- Young, M., & Smith, M. A. (2022). Standards And Evaluation Of Healthcare Quality, Safety, and Person Centered Care. PubMed; StatPearls Publishing.  
<https://www.ncbi.nlm.nih.gov/books/NBK576432/>